Revolutionizing Pharmacy: The Role of Emerging Nanomaterial-Based Sensors in Drug Analysis and Healthcare

Musidipalli Hymavathi[1]

[1]Formerly at Department of Nanotechnology, Andhra University

Freelance Biomedical Researcher

Abstract

Recent advancements in nanotechnology have significantly reshaped pharmaceutical science, particularly in the fields of drug detection, delivery, and therapeutic monitoring. This review highlights the critical role of emerging nanomaterial-based sensors—including carbon dots (CDs), MXenes, carbon nanotubes (CNTs), silver nanoparticles (AgNPs), gold nanoparticles (AuNPs), and polymeric nanocomposites—in enhancing modern drug analysis and healthcare solutions. These materials, known for their customizable physicochemical traits, high surface-to-volume ratios, and inherent biocompatibility, support ultra-sensitive and real-time sensing of pharmaceutical compounds, disease biomarkers, and pathogens. This article provides an in-depth discussion on their sensing mechanisms, synthesis approaches, and practical pharmaceutical applications, along with the current limitations related to toxicity, reproducibility, and scalability. It also explores future opportunities in integrating these nanotechnologies into personalized diagnostics, drug delivery systems, and wearable medical devices.

Keywords

Nanomaterials, Biosensors, Drug Detection, Carbon Dots, MXenes, Carbon Nanotubes, Gold Nanoparticles, Silver Nanoparticles, Theranostics, Personalized Healthcare.

1. Introduction

The evolution of personalized medicine has amplified the demand for advanced, accurate, and rapid drug analysis methods. Traditional analytical tools, while effective, often fall short in terms of sensitivity, response time, and adaptability to point-of-care settings. Nanotechnology bridges this gap, enabling multifunctional biosensors with enhanced sensitivity and specificity. Nanomaterials, due to their unique surface chemistry, electrical properties, and tunable size, have emerged as powerful tools in pharmaceutical research. They offer promising capabilities for drug monitoring, quality control, diagnostics, and targeted therapy—all within compact and scalable platforms.

2. Overview of Nanomaterials for Sensing



Figure 1. Schematic of different nanomaterials used for sensing

A wide array of nanomaterials has been engineered for sensing applications due to their high reactivity, functional surface area, and compatibility with biological environments. Materials such as carbon dots, MXenes, CNTs, AgNPs, and AuNPs have gained significant attention. These nanoscale structures can be functionalized with specific ligands, biomolecules, or chemical groups to improve selectivity, sensitivity, and stability. Their ability to operate in diverse matrices—ranging from bodily fluids to pharmaceutical formulations—makes them highly valuable for real-time drug monitoring and clinical diagnostics.



Figure 2. Classification of Nanomaterials and their Pharmaceutical functions

3. Sensing Mechanisms of Nanomaterials

Nanomaterial-based sensors operate through various detection strategies, each suited to specific analytes and environments:

- **Fluorescent and Photoluminescent Sensing** (CDs, AuNPs): Utilize mechanisms such as Förster Resonance Energy Transfer (FRET), Inner Filter Effect (IFE), and Photoinduced Electron Transfer (PET) to enable high-resolution optical sensi



Figure 3. Schematic of different sensing mechanisms used by nanomaterials.



Figure 4. Types of sensing mechanisms in Nanomaterial based sensors

- **Electrochemical Detection** (MXenes, CNTs): Leverages excellent electrical conductivity to detect analyte-induced current or voltage changes with high sensitivity.

- **Colorimetric Sensing** (AgNPs, AuNPs): Based on surface plasmon resonance (SPR), offering visible and rapid signal generation upon interaction with target drugs or biomarkers.

- **Photoelectrochemical (PEC) Sensing**: Combines light and electrochemical inputs to achieve improved detection performance, particularly for low-abundance pharmaceutical compounds.

These approaches can achieve detection limits as low as the femtomolar range, outperforming many traditional analytical techniques.

Table 1. Summary of nanomaterials and their pharmaceutical sensing targets.

Sensing Mechanism	**Applicable Nanomaterials**	**Detection Limits (Typical Range)**	**Representative Drug Analytes**	**Key Advantages**
Fluorescence / Photoluminesce	Carbon Dots (CDs), Gold	Nanomolar to femtomolar	Paracetamol, Azithromycin,	High sensitivity, tunable

nce (PL)	Nanoparticles (AuNPs)		Clonazepam, Gentamicin	emission, real-time imaging, biocompatible
Electrochemical Sensing	MXenes, Carbon Nanotubes (CNTs), AuNPs	Picomolar to nanomolar	Dopamine, Sertraline, Fluoxetine, Imipramine, Rifampicin	Rapid detection, portable setup, suitable for in-field and clinical use
Photoelectrochemical (PEC) Sensing	MXenes, AuNPs	Picomolar to femtomolar	Dopamine, Antibiotic residues	Combines optical and electrochemical precision, high specificity
Colorimetric/ SPR-based	AgNP-PNCs, AuNPs	Micromolar to nanomolar	Kanamycin, H_2S(oral gases), Breast cancer cells	Simple, visual detection, low cost, ideal for point- of- care tools
Forster Resonance Energy Transfer (FRET)	CDs, AuNPs	Nanomolar to picomolar	Curcumin, Cancer biomarkers	Enables multiplexed detection and signal amplification
Inner Filter Effect (IFE)	CDs	Nanomolar	Azithromycin, Baicalein	Simplified design, suitable for small molecules
Static/ Dynamic	CDs, CNTs	Nanomolar to	Nimesulide,	Precise Kinetic

Quenching		picomolar	Tetracycline, Atorvastatin	differentiation, adaptable for many analytes



Figure 5. Workflow for nanomaterial-based sensor development.

4. Pharmaceutical Applications

4.1 Drug Detection and Quality Assurance

Nanomaterials such as CDs and MXenes offer precise and ultra-sensitive detection of a wide range of pharmaceutical agents, including antibiotics, analgesics, and cancer therapeutics. These sensors enable real-time assessment of drug concentration in biological fluids and commercial formulations, enhancing pharmaceutical quality control and dosage accuracy.

4.2 Drug Delivery and Theranostics

CNTs and AuNPs are widely employed as multifunctional carriers that facilitate controlled drug release and simultaneous therapeutic monitoring. CDs and AgNP-based composites are also being developed for site-specific delivery and combined imaging-therapy applications, particularly in oncology.



Figure 6. Mechanism of targeted drug delivery using functionalized nanocarriers.

4.3 Clinical Diagnostics

Sensitive detection of biomarkers for cancer, infections, and neurological disorders is now feasible through nanomaterial-based platforms. These systems, particularly those involving AuNPs, AgNPs, and CDs, support early diagnosis by detecting trace levels of disease indicators in complex biological samples.

4.4 Antimicrobial Applications

AgNPs demonstrate broad-spectrum antimicrobial activity and are integrated into medical coatings, wound dressings, and dental products. Their ability to disrupt microbial cell structures and inhibit DNA replication makes them highly effective for infection control.

4.5 Tissue Engineering and Regenerative Therapies

Nanostructured materials such as CNTs and AgNPs enhance the mechanical and biological performance of scaffolds used in bone repair and tissue regeneration. Their incorporation improves cell adhesion, proliferation, and healing outcomes.

Table 2. Comparison of sensing mechanisms, detection limits, and benefits.

Nanomaterial	**Key Properties**	**Sensing Mechanisms**	**Target Analytes/ Drugs**	**Detection Matrices**	**Pharmaceutical Application**
Carbon Dots (CDs)	High photoluminescence, water solubility, biocompatibility, easy surface modification	FRET, IFE, PET, ICT, Static/Dynamic Quenching	Paracetamol, Azithromycin, Nimesulide, Clonazepam, Curcumin, Rifampicin, Gentamicin	Serum, Plasma, Urine, Tablet, Milk, Water samples	Drug detection cancer cell imaging, quality control

Carbon Nanotubes (CNTs)	High electrical/ thermal conductivity large surface area, strong mechanical strength, modifiable	Electrochemical sensing, flourescence, adsorption	Dopamine, Serotonin, Morphine, Cocaine, Chlorpromazine, Impiramine, Acetylcholine, Insulin	Blood serum, Pharmaceutical formulations	Neurotransmitter, Monitoring, Biosensing, Transdermal drug delivery
MXenes	2D structure, metalic conductivity, hydrophilic, rich surface functionalities	Electrochemical, photoelectrochemical, optical sensing	Sertraline, DOpamine, Fluoxetine, Rifampicin, Kanamycin, Oxytetracycline	Urine, Milk, Water, Serum	Point-of-care drug testing, antibiotic residue detection
Silver Nanoparticles-Polymer Nanocomposites (AgNP-PNCs)	Antimicrobial, high conductivity, SPR properties, embedded in biocompatible polymers	Colorimetric, optical sensing	H_2S gas (oral health), breast cancer cells, dental diseases markers	Saliva, Tissue samples	Antimicrobial coatings, Oral biosensors, wound healing applications

Gold Nanoparticles (AuNPs)	Biocompatibility, strong SPR, easy functionalization, eco friendly synthesis options	Plasmonic,Electrochemical, Fluorescence, Quenching/ recovery	Kanamycin, Gentamicin, Dopamine, Cancer biomakers	Blood, Serum, Cancer cells	Drug delivery, photothermal therapy, biomaker detection, diagnostics

5. Challenges and Future Outlook

While nanomaterials offer exceptional promise, several critical challenges remain:

- **Toxicity and Safety**: Potential generation of reactive oxygen species (ROS) and long-term accumulation, especially with CNTs and metallic nanoparticles, necessitate thorough biocompatibility assessments.

- **Stability and Reproducibility**: Sensor performance may degrade over time due to environmental interference, surface fouling, or material degradation.

- **Scalability**: Mass production of consistent and high-quality nanomaterials is still technically and economically challenging.

- **Regulatory Barriers**: Lack of harmonized standards for safety, validation, and clinical testing hinders the transition from research to commercial deployment.

Table 3. Biocompatibility and toxicity concerns of commonly used nanomaterials.

Nanomaterial	Biocompatibility Profile	Toxicity Concerns	Contributing Factors

Carbon Dots (CDs)	Generally considerd low toxicity; favorable for in vivo use	Minimal, but photoblinking and degradation may affect performance	Synthesis route, functional groups, surface charge
Carbon Nanotubes (CNTs)	Biocompatible after functionalization; non-immunogenic	Potential cytotoxicity, Non biodegradable, accumulation in organs	Length diameter, metal catalyst residues, aggregation
MXenes	Promising biocompatibility tunable surface groups	Limited studies, potential oxidative stress in biological systems	HF etching residues, layer thickness, surface terminations
Silver Nanoparticles (AgNPs)	Biocompatible when embedded in polymers	Dose-dependent cytotoxicity; oxidative stress and DNA damage	Particle size, concentration, ion release, aggregation
Gold Nanoparticles (AuNPs)	High biocompatibility, especially green synthesized variants	Risk of long term accumulation and tissue retention	Size, Shape, Surface Coating, Exposure time

Emerging Directions:

- **Integrated Multi-Modal Sensors**: Combining optical, thermal, and electrochemical modalities in a single sensor to boost performance and versatility.

- **Wearable and Implantable Devices**: Development of skin-mounted and implantable biosensors for continuous health monitoring and personalized drug therapy.



Figure 7. Wearable biosensor applications for real-time pharmaceutical monitoring.

- **Eco-Friendly Synthesis**: Emphasis on green and sustainable production methods to reduce environmental impact and improve material safety.

- **Regulatory Alignment**: Creation of universal validation protocols and safety frameworks to enable clinical translation of sensor technologies.

Table 4. Commercial and experimental nanobiosensors and their applications.

Sensor Type	**Nanomaterial used**	**Target Drug/ Analyte**	**Detection Matrix**	**Development stage**	**Applications**
Fluorescent sensor	Carbon Dots (CDs)	Nimesulide, Clonazepam, Curcumin, Tetracycline	Human serum, plasma, milk, tablet formulation	Research-stage	High-sensitivity drug detection and bioimaging tools
Electrochemical sensor	MXenes	Dopamine, Sertraline, Fluoxetine, Rifampicin	Urine, water,serum	Research-stage	Real-time neurotransmitter and antidepressant monitoring
Optical Fiber sensor	Gold Nanoparticles (AuNPs)	Kanamycin, cancer Biomarkers	Blood, cancer cells	Research-stage	Non-invasive cancer diagnostics and point-of-care biosensing
Colorimetric sensor	AgNP-Polymer Nanocomposites	H_2S (oral gas for dental disease), mCF- 7 breast cancer cells	Saliva, tissue samples	Research-stage	Wearable biosensors for oral health and early cancer detection
Electrochemi	Carbon	Cocaine,	Serum,	Prototype/	Portable

cal strip sensor	Nanotubes (CNTs)	Dopamine, Serotonin	pharmaceutical solutions	lab validation	drug abuse and neurochemical detection systems
Wearable mouthguard sensor	AuNPs embedded in polymer	H_2S (halitosis indicator)	Oral cavity	Prototype stage	Real-time dental disease monitoring with visible color shift
SPR-based Digital sensor	AuNPs	Allergy biomakers, infectious diseases	Blood, serum	Research-stage	Single-molecule detection with high specificity for disease diagnosis



Figure 8. Mind map of nanomaterials and their biomedical roles

6. Conclusion

Nanomaterial-based biosensors are redefining how pharmaceutical compounds and disease biomarkers are detected, monitored, and delivered. Their exceptional sensitivity, tunability, and adaptability position them as foundational tools in next-generation medical diagnostics and personalized treatments. Advancing these technologies through improved safety, scalability, and clinical validation will be critical to unlocking their full potential in real-world healthcare environments.

7. Acknowledgement

The author sincerely acknowledges the scientific community, funding bodies, and research institutions contributing to the advancement of nanomaterial-based sensing technologies in pharmaceutical and biomedical domains.

References

1. Ge, C., Du, J., Zhao, L., Wang, L., Liu, Y., Li, D., ... & Zhao, Y. (2011). Binding of blood proteins to carbon nanotubes reduces cytotoxicity. Proceedings of the National Academy of Sciences, 108(41), 16968–16973.
2. Lim, S. Y., Shen, W., & Gao, Z. (2015). Carbon quantum dots and their applications. Chemical Society Reviews, 44(1), 362–381.
3. Anasori, B., Lukatskaya, M. R., & Gogotsi, Y. (2017). 2D metal carbides and nitrides (MXenes) for energy storage. Nature Reviews Materials, 2(2), 16098.
4. Dykman, L., & Khlebtsov, N. (2012). Gold nanoparticles in biomedical applications: Recent advances and perspectives. Chemical Society Reviews, 41(6), 2256–2282.
5. Franci, G., Falanga, A., Galdiero, S., Palomba, L., Rai, M., Morelli, G., & Galdiero, M. (2015). Silver nanoparticles as potential antibacterial agents. Molecules, 20(5), 8856–8874.
6. Yan, Y., Chen, J., Lin, H., Wang, Y., & Wang, C. (2020). Recent advances in polymer-based nanomaterials for drug delivery. Chemical Engineering Journal, 384, 123681.
7. Li, H., Kang, Z., Liu, Y., & Lee, S.-T. (2012). Carbon nanodots: synthesis, properties and applications. Journal of Materials Chemistry, 22(46), 24230–24253.
8. Zhang, X., Wang, W., Yu, X., & Wang, Y. (2021). MXene-based electrochemical sensors: Recent progress and perspectives. Sensors and Actuators B: Chemical, 330, 129324.

9. Barati, A., Karimi, M., & Yousefi, H. (2022). Nanomaterial-based wearable biosensors for real-time monitoring of physiological and biochemical markers. Biosensors and Bioelectronics, 197, 113808.
10. Iravani, S., & Varma, R. S. (2020). Green synthesis, biomedical and biotechnological applications of carbon and graphene quantum dots. A review. Environmental Chemistry Letters, 18(3), 703–727.
11. Yang, M., Xie, C., & Lu, H. (2025). Advances in MXene-Based Electrochemical Sensors for Multiplexed Detection in Biofluids. International Journal of Molecular Sciences, 26(11), 5368.
12. Lim, S. Y., Shen, W., & Gao, Z. (2015). Carbon quantum dots and their applications. Chemical Society Reviews, 44(1), 362–381.
13. Li, H., Kang, Z., Liu, Y., & Lee, S.-T. (2012). Carbon nanodots: synthesis, properties and applications. Journal of Materials Chemistry, 22(46), 24230–24253.
14. Yuan, Y., et al. (2020). Carbon nanodots as sensitive and selective nanomaterials in pharmaceutical analysis. Journal of Materials Science, 57(12), 1–15.
15. Dykman, L., & Khlebtsov, N. (2012). Gold nanoparticles in biomedical applications: Recent advances and perspectives. Chemical Society Reviews, 41(6), 2256–2282.
16. Franci, G., Falanga, A., Galdiero, S., Palomba, L., Rai, M., Morelli, G., & Galdiero, M. (2015). Silver nanoparticles as potential antibacterial agents. Molecules, 20(5), 8856–8874.
17. Anasori, B., Lukatskaya, M. R., & Gogotsi, Y. (2017). 2D metal carbides and nitrides (MXenes) for energy storage and sensing. Nature Reviews Materials, 2, 16098.
18. Zhang, X., Wang, W., Yu, X., & Wang, Y. (2021). MXene-based electrochemical sensors: recent progress and perspectives. Sensors and Actuators B: Chemical, 330, 129324.
19. Yan, Y., Chen, J., Lin, H., Wang, Y., & Wang, C. (2020). Recent advances in polymer-based nanomaterials for drug delivery. Chemical Engineering Journal, 384, 123681.
20. Mathew, M., & Rout, C. S. (2021). Electrochemical biosensors based on $Ti_3C_2T_x$ MXene: future perspectives for on-site analysis. Microchimica Acta.
21. Alwarappan, S., Nesakumar, N., Sun, D., Hu, T.-Y., & Li, C.-Z. (2022). Recent advances in electrochemical sensing using MXene composites. Biosensors and Bioelectronics, 205, 113943.
22. Chandra, A., Prasad, S., Gigli, G., & del Mercato, L. L. (2020). Fluorescent nanoparticles for sensing. arXiv preprint.
23. Mathew, A., & Mishra, B. (2018). Optical detection using carbon dots–AuNP hybrids for thiol drugs. Plasmonics, 13, 2239–2248.

24. D’souza, T. P., & Chellappan, D. (2023). Green synthesis of nanomaterials for biosensors and drug delivery. arXiv preprint.
25. Cambria, E.; Das, D.; Bandyopadhyay, S.; Feraco, A. Affective computing and sentiment analysis. In A Practical Guide to Sentiment Analysis; Springer: Cham, Switzerland, 2017; pp. 1–10.
26. Mubarak, N.M.; Abdullah, E.C.; Jayakumar, N.S.; Sahu, J.N. An overview on methods for the production of carbon nanotubes. J. Ind. Eng. Chem. 2014, 20, 1186–1197.
27. Duclaux, L. Review of the doping of carbon nanotubes (multiwalled and single-walled). Carbon 2002, 40, 1751–1764.
28. Mokhtari, A.; Karimi-Maleh, H.; Ensafi, A.A.; Beitollahi, H. Application of modified multiwall carbon nanotubes paste electrode
29. for simultaneous voltammetric determination of morphine and diclofenac in biological and pharmaceutical samples. Sens. Actuators B Chem. 2012, 169, 96–105.
30. García, J.M.; Pablos, J.L.; García, F.C.; Serna, F. Sensory polymers for detecting explosives and chemical warfare agents. Industrial Applications for Intelligent Polymers and Coatings; Springer: Cham, Switzerland, 2016; pp. 553–576.
31. Emerich, D.F.; Thanos, C.G. Targeted nanoparticle-based drug delivery and diagnosis. J. Drug Target. 2007, 15, 163–183.
32. Zhang, Y.; Liu, X.; Li, L.; Guo, Z.; Xue, Z.; Lu, X. An electrochemical paracetamol sensor based on layer-by-layer covalent attachment of MWCNTs and a G4.0 PAMAM modified GCE. Anal. Methods 2016, 8, 2218–2225.